Navidea Biopharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
- President to Provide Business and Development Program Updates -
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Thomas Tulip, President and Chief Business Officer, will participate at the Jefferies 2013 Global Healthcare Conference on June 3-6, 2013 at the Grand Hyatt in New York City, NY. Dr. Tulip will provide an update of the Company and its development programs on Tuesday, June 4, 2013 at 2:30 PM EDT.
Investors and the public are invited to listen to a live webcast of Dr. Tulip's presentation at http://wsw.com/webcast/jeff77/navb/. Following the conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek®, NAV4694, NAV5001 and RIGScanTM - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Executive VP & CFO
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
KEYWORDS: United States North America New York Ohio
The article Navidea Biopharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.